The CD200/CD200R mechanism in mesenchymal stem cells' regulation of dendritic cells.
CD200/CD200R
Mesenchymal stem cells
dendritic cells
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
01
2021
accepted:
12
04
2021
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
To investigate the CD200/CD200R pathway mechanism in mesenchymal stem cells' (MSC) regulation of dendritic cells (DC) (MSc). We collected marrow samples from 40 patients admitted to our hospital from January 2018 to December 2019. The bone marrow MSCs were cultivated, and the peripheral blood mononuclear cells (PBMC) and peripheral blood DC were isolated to establish an in vitro immune response model. The expressions of the CD200 molecule on the surface of MSC were measured. Anti-CD200 blocking antibodies were added to the culture system to observe the effect of the PBMC differentiation and the immature DC (imDC) to mature DC (mDC). Then the impact of the different positive rates of CD200 in the same MSC on imDC maturity was measured. After adding mitogen pHA, the IL-4, IL-10, and TNF-α secretions were increased (all P<0.05), and the OD value of the PBMC+pHA group was higher than it was in the PBMC group. After stimulated by pHA, the CD200 of the MSC group was higher than it was in the MSC+PBMC group (P<0.05). The MSC+PBMC group co-culture inhibited the development of imDC to mDC. Adding anti-CD200 antibodies to the MSC+PBMC co-culture system, MSC could still inhibit the differentiation of PBMC to imDC, and MSC had a significant inhibition effect on imDC to mDC maturation (P=0.006). The addition of MSC reduces the maturation markers on the surface of mDC (P<0.05). The addition of MSC inhibited the ability of mDC to stimulate PBMC (P The mechanism by which MSC inhibits DC may be achieved through the CD200/CD200R pathway, and the CD200/CD200R pathway mainly acts on the process from imDC to mDC.
Types de publication
Journal Article
Langues
eng
Pagination
9607-9613Informations de copyright
AJTR Copyright © 2021.
Déclaration de conflit d'intérêts
None.
Références
Cell Mol Life Sci. 2017 Jul;74(13):2345-2360
pubmed: 28214990
Cells. 2019 Jul 28;8(8):
pubmed: 31357692
Cell Transplant. 2015;24(3):339-47
pubmed: 25622293
Biotechnol Lett. 2018 Oct;40(9-10):1425-1433
pubmed: 29740779
Biotechnol Lett. 2014 Jun;36(6):1335-41
pubmed: 24562407
Iran J Allergy Asthma Immunol. 2020 Oct 18;19(5):484-496
pubmed: 33463116
Stem Cells Transl Med. 2017 Dec;6(12):2173-2185
pubmed: 29076267
Stem Cell Res Ther. 2016 Aug 11;7(1):107
pubmed: 27515308
Nat Rev Immunol. 2008 Sep;8(9):726-36
pubmed: 19172693
Aging Dis. 2016 Oct 1;7(5):623-634
pubmed: 27699085
Exp Mol Med. 2013 Nov 15;45:e54
pubmed: 24232253
Immunol Lett. 2012 Aug 30;146(1-2):50-6
pubmed: 22575528
Exp Mol Med. 2018 Jan 12;50(1):e425
pubmed: 29328072
Nat Biotechnol. 2014 Mar;32(3):252-60
pubmed: 24561556
PLoS One. 2013 Aug 05;8(8):e72831
pubmed: 23940819
Cell Mol Immunol. 2019 Dec;16(12):908-920
pubmed: 30778166
J Cell Mol Med. 2016 Apr;20(4):655-65
pubmed: 26773707
Pol Merkur Lekarski. 2017 Mar 21;42(249):97-100
pubmed: 28333899
PLoS One. 2012;7(2):e31671
pubmed: 22363701
Brain Res Bull. 2019 Nov;153:324-333
pubmed: 31589902
Blood. 2008 Mar 1;111(5):2631-5
pubmed: 18086871